l carnitina inyeccion subcutanea con alcachofa πΌππ©ππ«π π©πͺ π’ππ©πππ€π‘ππ¨π’π€ ππ ππ€π§π’π π£ππ©πͺπ§ππ‘ ΒΏππ π¨πππ£π©ππ¨ π₯ππ¨πππ, ππ€π£ π₯π€ππ ππ£ππ§ππΜπ π€ ππ£ππ‘ππ’πππβ ππ¨ π’π€π’ππ£π©π€ ππ πππ§π‘π π π©πͺ ππͺππ§π₯π€ π‘π€ π¦πͺπ π£ππππ¨ππ©π π₯ ANTIOB β REDUCTOR Y
Description
In the multivariate analysis, l-carnitine administration (OR 3.51, 95% CI 1.239.99, p = 0.019) and baseline NIRS data of 0.07 mMmm (OR 5.21, 95% CI 1.6916.0, p = 0.0041) were found as significant independent factors (Table 3)
total lesions: 45.6% vs
Box 2 presents the consensus panels recommendations for NKRT
INGREDIENTES: L- Carnitina Tartarato, Cafena Anidra e Antiumectante Dixido de Silcio
